THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
TORONTO, March 20, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is happy to announce that it has closed an preliminary tranche (“First Tranche”) of the providing introduced on March 10, 2026 and March 11, 2026 (jointly, the “Announcement NRs”) and has issued 3,750 Debenture Devices (as outlined within the Announcement NRs) for $3,750,000.
The Corporate will use the proceeds from the First Tranche for the continuing construction of the Corporate’s trade style and for normal running capital functions.
One director of the Corporate (the “Director Subscriber”) participated within the Providing (as outlined within the Announcement NRs) and subscribed for Debenture Devices representing mixture gross proceeds of $300,000. The participation by means of the Director Subscriber within the Providing constitutes a “related party transaction” as outlined underneath Multilateral Device 61-101 – Coverage of Minority Safety Holders in Particular Transactions (“MI 61-101”). The Corporate is depending at the exemptions from the formal valuation and minority shareholder approval necessities of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the honest marketplace price of the subject material of, nor the honest marketplace price of the honour for, the transaction exceeds 25% of the Corporate’s marketplace capitalization, as made up our minds based on MI 61-101. The Corporate didn’t report a subject matter exchange document in recognize of the comparable birthday party sides of the Director Subscriber’s participation within the Providing no less than 21 days prior to the final of the Providing, which the Corporate deems cheap within the instances so as to expedite the finishing touch of the Providing.
Debt Agreement
As well as, the Corporate has finished an preliminary batch of the Debt Agreement (as outlined within the Announcement NRs) by means of issuing an mixture of 370,457 Magnificence B subordinate balloting stocks within the Corporate (each and every, a “Class B Share”) to settle roughly $1,117,727 of debt owed to positive arm’s period collectors and insiders of the Corporate.
The participation by means of insiders of the Corporate within the Debt Agreement constitutes a “related party transaction” as outlined underneath Multilateral Device 61-101 – Coverage of Minority Safety Holders in Particular Transactions (“MI 61-101”). The Corporate is depending at the exemptions from the formal valuation and minority shareholder approval necessities of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the honest marketplace price of the subject material of, nor the honest marketplace price of the honour for, the transaction exceeds 25% of the Corporate’s marketplace capitalization, as made up our minds based on MI 61-101. The Corporate didn’t report a subject matter exchange document in recognize of the comparable birthday party sides of the Debt Agreement no less than 21 days prior to the final of the Debt Agreement, which the Corporate deems cheap within the instances so as to expedite the finishing touch of the Debt Agreement.
All quantities on this press free up are expressed in Canadian greenbacks.
The securities described herein have now not been, nor will they be, registered underneath the USA Securities Act of 1933, as amended, and will not be introduced or offered in the USA or to, or for the account or advantage of, U.S. individuals absent registration or an appropriate exemption from the registration necessities. This press free up shall now not represent an be offering to promote or the solicitation of an be offering to shop for nor shall there be any sale of the securities in any State by which such be offering, solicitation or sale can be illegal.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical corporate devoted to development a portfolio of cutting edge property and biotech answers for the remedy of difficult neurodegenerative and metabolic issues and alcohol misuse issues with drug applicants in numerous phases of construction. Thru its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is targeted at the analysis and construction of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity proven to forestall and opposite myelin degradation, the underlying mechanism of more than one sclerosis, in preclinical fashions. Quantum BioPharma invented UNBUZZD™ and spun out its OTC model to an organization, Celly Vitamin Corp. (“Celly Nutrition”), led by means of trade veterans. Quantum BioPharma keeps possession of 25.71% (as of June 30, 2024) of Celly Vitamin at www.unbuzzd.com. The settlement with Celly Vitamin additionally comprises royalty bills of seven% of gross sales from unbuzzd™ till bills to Quantum BioPharma general $250 million. As soon as $250 million is reached, the royalty drops to three% in perpetuity. Moreover, Quantum BioPharma keeps a big tax loss elevate ahead of roughly C$130 million and may well be applied one day to offset tax payable duties in opposition to long run income. Quantum BioPharma keeps 100% of the rights to expand an identical product or choice formulations particularly for pharmaceutical and clinical makes use of.
Ahead-Having a look Knowledge
Ahead-looking knowledge on this press free up is in accordance with positive assumptions and anticipated long run occasions, together with however now not restricted to: the Corporate has the facility to finish further tranches of the Providing and the Debt Agreement.
Those statements contain identified and unknown dangers, uncertainties and different elements, which might purpose precise effects, efficiency or achievements to fluctuate materially from the ones expressed or implied by means of such statements, together with however now not restricted to: dangers in the case of the Corporate’s trade and operations in most cases; and the reader is instructed to consult with additional info in the case of Quantum BioPharma, together with its annual knowledge shape, which will also be situated at the SEDAR+ site at www.sedarplus.ca and at the EDGAR phase of the USA Securities and Alternate Fee’s site at www.sec.gov for a extra whole dialogue of such chance elements and their possible results.
Readers are cautioned that the foregoing record isn’t exhaustive. Readers are additional cautioned to not position undue reliance on forward-looking statements, as there will also be no assurance that the plans, intentions or expectancies upon which they’re positioned will happen. Such knowledge, even if regarded as cheap by means of control on the time of preparation, might turn out to be flawed and precise effects might fluctuate materially from the ones expected.
Ahead-looking statements contained on this press free up are expressly certified by means of this cautionary commentary and replicate the Corporate’s expectancies as of the date hereof and are matter to modify thereafter. The Corporate undertakes no legal responsibility to replace or revise any forward-looking statements, whether or not because of new knowledge, estimates or reviews, long run occasions or effects or another way or to give an explanation for any subject matter distinction between next precise occasions and such forward-looking knowledge, excluding as required by means of appropriate regulation.
Contacts:
